← All trials
NCT05377827
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Jun 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- May 17, 2022
- Last posted
- Sep 29, 2022
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Washington University in St. LouisLead sponsor
- Washington University in St. LouisOverall official - principal investigator
- Wugen, Inc.Collaborator
Drugs studied
Indications studied
- Intestinal Neoplasms
- Lymphoma
- Lymphoma, Non-Hodgkin
- Mycosis Fungoides
- Sezary Syndrome
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Prolymphocytic, T-Cell
- Leukemia, Myeloid, Acute
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Extranodal NK-T-Cell
- Enteropathy-Associated T-Cell Lymphoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.